OS Therapies raises $7.2 million from warrant exercises at a reduced price
OS Therapies said on October 15, 2026 that seven holders exercised or pre-funded 5,517,253 existing warrants at a reduced price of $1.30 per share, bringing in about $7.2 million in gross proceeds before fees. In exchange, the company issued new five-year warrants for the same number of shares at $1.40, and the company says the offer could bring about $12.3 million in total if all existing warrants are exercised. Because the new warrants add potential share issuance, the deal provides near-term capital but also raises potential dilution for existing shareholders.
Key points
- Initial closing on October 15, 2026: seven holders exercised or pre-funded warrants for 5,517,253 shares at $1.30 per share, for about $7.2 million gross.
- New warrants issued for 5,517,253 shares at $1.40 per share, expiring five years from issuance; if all existing warrants are exercised, up to 9,448,060 new warrant shares could be issued.
- Company agreed to pay a solicitation agent a 7.0% cash fee on gross proceeds plus a $25,000 expense allowance; the offer expires at 11:59 p.m. Eastern on October 30, 2026.
- Company plans to file a resale registration statement by November 30, 2026, and says proceeds will fund Herlystic clinical, regulatory and commercial preparation work.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.